U.S. Markets closed
  • S&P 500

    3,841.94
    +73.47 (+1.95%)
     
  • Dow 30

    31,496.30
    +572.20 (+1.85%)
     
  • Nasdaq

    12,920.15
    +196.65 (+1.55%)
     
  • Russell 2000

    2,192.21
    +45.29 (+2.11%)
     
  • Crude Oil

    66.28
    +2.45 (+3.84%)
     
  • Gold

    1,698.20
    -2.50 (-0.15%)
     
  • Silver

    25.30
    -0.17 (-0.65%)
     
  • EUR/USD

    1.1916
    -0.0063 (-0.5243%)
     
  • 10-Yr Bond

    1.5540
    +0.0040 (+0.26%)
     
  • Vix

    24.66
    -3.91 (-13.69%)
     
  • GBP/USD

    1.3834
    -0.0060 (-0.4344%)
     
  • USD/JPY

    108.3600
    +0.3840 (+0.3556%)
     
  • BTC-USD

    50,549.18
    +2,346.82 (+4.87%)
     
  • CMC Crypto 200

    982.93
    +39.75 (+4.21%)
     
  • FTSE 100

    6,630.52
    -20.36 (-0.31%)
     
  • Nikkei 225

    28,864.32
    -65.78 (-0.23%)
     

RedHill Biopharma Expands Opaganib Global COVID-19 Study To US

  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Following the FDA review of data from the U.S. Phase 2 study of opaganib and receipt of its recommendations, RedHill Biopharma Ltd (NASDAQ: RDHLplans to expand its global Phase 2/3 study of opaganib in patients with severe COVID-19 to the U.S.

  • The study's expansion to the U.S. will help further speed-up enrollment, expand the study to eight countries and approximately 40 recruiting sites. The 464-patient study is over 50% enrolled, and topline data expected in the second quarter of 2021.

  • The global Phase 2/3 study recently underwent a positive DSMB futility review, which is suggestive that the study has the potential for a positive outcome.

  • In December last year, the company announced positive topline data from the non-powered U.S. Phase 2 study with opaganib in patients with COVID-19 pneumonia and demonstrated positive safety and efficacy signals.

  • Opaganib is an orally-administered sphingosine kinase-2 (SK2) inhibitor with demonstrated antiviral, anti-inflammatory, and anti-thrombotic activity that targets a human cell component involved in viral replication.

  • Price Action: RDHL shares are down 3.0397% at $10.95 in the premarket trading on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.